التفاصيل البيبلوغرافية
| العنوان: |
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer |
| المؤلفون: |
Bajetta, Emilio, Floriani, Irene, Di Bartolomeo, Maria, Labianca, Roberto, Falcone, Alfredo, Di Costanzo, Francesco, Comella, Giuseppe, Amadori, Dino, Pinto, Carmine, Carlomagno, Chiara, Nitti, Donato, Daniele, Bruno, Mini, Enrico, Poli, Davide, Santoro, Armando, Mosconi, Stefania, Casaretti, Rossana, Boni, Corrado, Pinotti, Graziella, Bidoli, Paolo, Landi, Lorenza, Rosati, Gerardo, Ravaioli, Alberto, Cantore, Maurizio, Di Fabio, Francesca, Marchet, Alberto, for the ITACA-S (Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach trial) Study Group, Floriani, I., Rulli, E., Cropalato Di Tullio, M., Poli, D., Galli, F., Biagioli, E., De Simone, I., Mangano, S., Tonato, M., Zucca, E., Valsecchi, MG., Bajetta, E., Di Bartolomeo, M., Labianca, R., Amadori, D., Falcone, A., Di Costanzo, F., Daniele, B., Pinto, C., Comella, G., Nitti, D., Mini, E., De Placido, S., Marchet, A., Catena, L., Schiavo, M., Pinotti, G., Proserpio, I., Rosati, G., Bordonaro, R., Cordio, S., Burrafato, G., Bochicchio, A.M., Aieta, M., Fazio, N., Spada, F., Amoroso, V., Marini, G., Soto Parra, H., Novello, G., Massidda, B., Ionta, M.T., Comandè, M., Venezia, R., Bertolini, A., Menatti, E., Zanlorenzi, L., Colombo, A., Iop, A., Bonura, S., Mazza, E., Viganò, M., Ardizzoia, A., Dell'Oro, S., Lo Re, G., Santeufemia, D., Buonadonna, A., Luisi, D., Ucci, G., Di Lucca, G., Bonetti, A., Bergamo, F., Alù, M., Vastola, F., Marchetti, P., Corsi, D.C., Massa, E., Di Pinto, G., Duro, M., Oliani, C., Franchini, M., Inzoli, A., Gebbia, N., Repetto, L., Rota, S., Frontini, L., Mosconi, S., Quadri, A., De Grossi, S., Bidoli, P., Cazzaniga, M.E., Villa, F., Foa, P., Ferrari, D., Aitini, E., Rabbi, C., Barni, S., Petrelli, F., Giordano, M., Luchena, G., Pirovano, M., Nasisi, A., Catalano, V., Giordani, P., Zaniboni, A., Leone, F., Ferrario, S., Beretta, G.D., Menichetti, E.T., Conte, D., Mari, D., Giannicola, R., Pierantoni, C., Luporini, A.G., Ravaioli, A., Tassinari, D., Nicolini, M., Frassineti, G.L., Turci, D., Zumaglini, F., Tamberi, S., Piancastelli, A., Cruciani, G., Landi, L., Minuti, G., Cantore, M., Orlandi, M., Mambrini, A., Ciarlo, A., Cavaciocchi, D., Del Monte, F., Ricci, S., Brunetti, M.I., Lencioni, M., Sisani, M., Sozzi, P., Granetto, C., Chiara, S., Galetto, A.S., Ribecco, A.S., DeCensi, A., Ciuffreda, L., Baldini, E.E., Camisa, R., Todeschini, R., Santoro, A., Rimassa, L., Carnaghi, C., Pressiani, T., Boni, C., Rondini, E., Gnoni, R., Gasperoni, S., Cavanna, L., Palladino, M.A., Mattioli, R., Laici, G., Pucci, F., Alessio, M.D., Bernardini, I., Tomasello, G., Baldino, G., Rossetti, R., Giaquinta, S., Di Fabio, F., Rijas Llimpe, F.L., Brandes, A.A., Marzola, M., Montesarchio, V., Rea, A., Genua, G., Casaretti, R., Silvestro, L., Montano, M., Sarobba, M.G., Sanna, G., Filippelli, G., Dima, G., Greco, E., Roselli, M., Natale, D., Condemi, G., Fumi, G., Tafuto, S., Masullo, P., Tiberio, G., de Manzoni, G., Fiorentini, G., Mazzanti, R., Carlomagno, C., De Stefano, A., Cartenì, G., Otero, M. |
| بيانات النشر: |
Oxford University Press |
| سنة النشر: |
2014 |
| المجموعة: |
HighWire Press (Stanford University) |
| مصطلحات موضوعية: |
Original article |
| الوصف: |
<$O_ST_ABS>Background<$C_ST_ABS>Some trial havedemonstrated a benefit of adjuvant fluoropirimidine with or without platinum compounds compared to surgery alone. ITACA-S study was designed to evaluate whether a sequential treatment of FOLFIRI (irinotecan plus 5-fluorouracil/folinic acid [5-FU/LV]) followed by docetaxel plus cisplatin improves disease free survival in comparison to 5-FU/LV in patients with radically resected gastric cancer. <$O_ST_ABS>Methods<$C_ST_ABS>Patients with resectable adenocarcinoma of the stomach or gastroesophageal junction were randomly assigned to either FOLFIRI (irinotecan 180 mg/m2 day one, LV 100 mg/m2 as two hour-infusion and 5-FU 400 mg/m2 as bolus, day one and day two followed by 600 mg/m2/day as 22-hour continuous infusion, q14 for four cycles) followed by docetaxel 75 mg/m2 day one, cisplatin 75 mg/m2 day one, q21 for three cycles (sequential arm) or De Gramont regimen (5-FU/LV arm). <$O_ST_ABS>Results<$C_ST_ABS>From February 2005 to August 2009, 1106 patients were enrolled, and 1100 included in the analysis: 562 in sequential and 538 in 5-FU/LV arm. With a median follow-up of 57.4 months, 581 patients recurred or died (297 sequential arm and 284 5FU/LV arm), and 483 died (243 and 240, respectively). No statistically significant difference was detected for both disease free (HR 1.00; 95%CI: 0.85-1.17; p=0.974) and overall survival (HR 0.98; 95%CI: 0.82-1.18; p=0.865). Five-year disease free and overall survival rates were 44.6% and 44.6%, 51.0% and 50.6% in sequential and 5FU/LV arm, respectively. <$O_ST_ABS>Conclusions<$C_ST_ABS>A more intensive regimen failed to show any benefit in disease free and overall survival versus monotherapy [ClinicalTrials.gov Identifier: NCT01640782]. |
| نوع الوثيقة: |
text |
| وصف الملف: |
text/html |
| اللغة: |
English |
| Relation: |
http://annonc.oxfordjournals.org/cgi/content/short/mdu146v1; http://dx.doi.org/10.1093/annonc/mdu146 |
| DOI: |
10.1093/annonc/mdu146 |
| الاتاحة: |
http://annonc.oxfordjournals.org/cgi/content/short/mdu146v1
https://doi.org/10.1093/annonc/mdu146 |
| Rights: |
Copyright (C) 2014, European Society for Medical Oncology |
| رقم الانضمام: |
edsbas.6397748 |
| قاعدة البيانات: |
BASE |